These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17822696)

  • 1. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats.
    Li YQ; Ji H; Zhang YH; Shi WB; Meng ZK; Chen XY; Du GT; Tian J
    Eur J Pharmacol; 2007 Dec; 577(1-3):100-8. PubMed ID: 17822696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
    De Godoy MA; Rattan S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats.
    Liu D; Yang D; He H; Chen X; Cao T; Feng X; Ma L; Luo Z; Wang L; Yan Z; Zhu Z; Tepel M
    Hypertension; 2009 Jan; 53(1):70-6. PubMed ID: 19029480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
    Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
    Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
    Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
    Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.
    Gohlke P; Weiss S; Jansen A; Wienen W; Stangier J; Rascher W; Culman J; Unger T
    J Pharmacol Exp Ther; 2001 Jul; 298(1):62-70. PubMed ID: 11408526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling.
    Takai S; Kirimura K; Jin D; Muramatsu M; Yoshikawa K; Mino Y; Miyazaki M
    Hypertens Res; 2005 Jul; 28(7):593-600. PubMed ID: 16335888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
    Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
    Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats.
    van Meel JC; Redemann N; Haigh RM
    Arzneimittelforschung; 1996 Aug; 46(8):755-9. PubMed ID: 9125273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
    Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
    Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats.
    Xu L; Liu Y
    Physiol Res; 2013; 62(4):351-9. PubMed ID: 23590610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
    Mervaala EM; Malmberg L; Teräväinen TL; Laakso J; Vapaatalo H; Karppanen H
    Br J Pharmacol; 1998 Jan; 123(2):195-204. PubMed ID: 9489606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow.
    Heinemann A; Sattler V; Jocic M; Wienen W; Holzer P
    Aliment Pharmacol Ther; 1999 Mar; 13(3):347-55. PubMed ID: 10102968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
    Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T
    Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
    Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
    Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E
    Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.